Wechselwirkungen von Dorzolamid und Timolol

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (Fachinformation zu Alogliptin und Metformin, Boxed Warning (umrahmter Warnhinweis))

CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (Fachinformation zu Atenolol und Chlortalidon, Gegenanzeigen)

Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. (Fachinformation zu Benazepril und Hydrochlorothiazid, Gegenanzeigen)

CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Fachinformation zu Bisoprolol und Hydrochlorothiazid, Gegenanzeigen)

CONTRAINDICATIONS Candesartan cilexetil and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to candesartan, to hydrochlorothiazide or to other sulfonamide-derived drugs. (Fachinformation zu Candesartan und Hydrochlorothiazid, Gegenanzeigen)

• In patients who have demonstrated allergic-type reactions to sulfonamides [ see Warnings and Precautions (5.7) ]. (Fachinformation zu Celecoxib, Gegenanzeigen)

Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed. (Fachinformation zu Chloroprocain, Vorsichtsmaßnahmen)

Hypersensitivity to this product or to other sulfonamide-derived drugs. (Fachinformation zu Chlorothiazid, Gegenanzeigen)

THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Fachinformation zu Chlortalidon, Gegenanzeigen)

Cidofovir injection is contraindicated in patients with a history of clinically severe hypersensitivity to probenecid or other sulfa-containing medications. (Fachinformation zu Cidofovir, Gegenanzeigen)

• Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (Fachinformation zu Dapagliflozin und Metformin, Boxed Warning (umrahmter Warnhinweis))

KEVEYIS is contraindicated in the following circumstances: Hypersensitivity to dichlorphenamide or other sulfonamides [see Warnings and Precautions (5.1) ] Concomitant use of KEVEYIS and high dose aspirin [see Warnings and Precautions (5.2) and Drug Interactions (7.1) ] Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS [see… (Fachinformation zu Diclofenamid, Gegenanzeigen)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin-containing products, including JALYN. (Fachinformation zu Dutasterid und Tamsulosin, Warnhinweise und Vorsichtsmaßnahmen)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (Fachinformation zu Empagliflozin und Metformin, Boxed Warning (umrahmter Warnhinweis))

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (Fachinformation zu Enalapril und Hydrochlorothiazid, Gegenanzeigen)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (Fachinformation zu Flecainid, Boxed Warning (umrahmter Warnhinweis))

Fosinopril sodium and hydrochlorothiazide is also contraindicated in patients who are hypersensitive to fosinopril, to any other ACE inhibitor, to hydrochlorothiazide, or other sulfonamide-derived drugs, or any other ingredient or component in the formulation. (Fachinformation zu Fosinopril und Hydrochlorothiazid, Gegenanzeigen)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g. , acute congestive heart failure), excessive alcohol intake, hepatic… (Fachinformation zu Glibenclamid und Metformin, Boxed Warning (umrahmter Warnhinweis))

• Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets.Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives. (Fachinformation zu Glimepirid, Gegenanzeigen)

• Hypersensitivity to sulfonamide derivatives. ▪ Known hypersensitivity to glipizide or any of the product's ingredients ( 4 ). ▪ Hypersensitivity to sulfonamide derivatives ( 4 ). (Fachinformation zu Glipizid, Gegenanzeigen)

In patients with hypersensitivity to sulfonamide-derived drugs. (Fachinformation zu Hydrochlorothiazid, Gegenanzeigen)

Known hypersensitivity to indapamide or to other sulfonamide-derived drugs. (Fachinformation zu Indapamid, Gegenanzeigen)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (Fachinformation zu Irbesartan und Hydrochlorothiazid, Gegenanzeigen)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (Fachinformation zu Linagliptin und Metformin, Boxed Warning (umrahmter Warnhinweis))

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (Fachinformation zu Lisinopril und Hydrochlorothiazid, Gegenanzeigen)

Patients receiving antibiotics and sulfonamides should generally not be treated with ganglion blockers. (Fachinformation zu Mecamylamin, Gegenanzeigen)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic… (Fachinformation zu Metformin, Boxed Warning (umrahmter Warnhinweis))

In addition, life-threatening arrhythmias may occur during anesthesia and surgery, and may require treatment with a beta-blocker or lidocaine. (Fachinformation zu Metirosin, Warnhinweise)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Fachinformation zu Metoprolol und Hydrochlorothiazid, Gegenanzeigen)

Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (Fachinformation zu Minoxidil, Boxed Warning (umrahmter Warnhinweis))

Hypotensive Agents Do not use BYSTOLIC with other β-blockers. (Fachinformation zu Nebivolol, Arzneimittelwechselwirkungen)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (Fachinformation zu Olmesartan, Amlodipin und Hydrochlorothiazid, Gegenanzeigen)

Avoid use of phentermine and topiramate extended-release capsules with other carbonic anhydrase inhibitors. (Fachinformation zu Phentermin und Topiramat, Warnhinweise und Vorsichtsmaßnahmen)

Use in patients with known history of an allergic reaction to sulfonamide derivatives. (Fachinformation zu Pioglitazon und Glimepirid, Gegenanzeigen)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (Fachinformation zu Pioglitazon und Metformin, Boxed Warning (umrahmter Warnhinweis))

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (Fachinformation zu Protamin, Boxed Warning (umrahmter Warnhinweis))

Because of the hydrochlorothiazide components, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (Fachinformation zu Quinapril und Hydrochlorothiazid, Gegenanzeigen)

Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (Fachinformation zu Rivastigmin, Arzneimittelwechselwirkungen)

• Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure ), excessive alcohol intake, hepatic… (Fachinformation zu Saxagliptin und Metformin, Boxed Warning (umrahmter Warnhinweis))

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (Fachinformation zu Sitagliptin und Metformin, Boxed Warning (umrahmter Warnhinweis))

CONTRAINDICATIONS Spironolactone and hydrochlorothiazide tablets are contraindicated in patients with anuria, acute renal insufficiency, significant impairment of renal excretory function, hypercalcemia, hyperkalemia, Addison's disease, and in patients who are allergic to thiazide diuretics or to other sulfonamide-derived drugs. (Fachinformation zu Spironolacton und Hydrochlorothiazid, Gegenanzeigen)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (Fachinformation zu Tamsulosin, Warnhinweise und Vorsichtsmaßnahmen)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Kidney stones: avoid use with other carbonic anhydrase inhibitors, drugs causing metabolic acidosis, or in patients on a ketogenic diet ( 5.13 ) (Fachinformation zu Topiramat, Warnhinweise und Vorsichtsmaßnahmen)

…Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension e Blood glucose-lowering… (Fachinformation zu Tranylcypromin, Arzneimittelwechselwirkungen)

Hypersensitivity Hypersensitivity to either drug in the preparation or to other sulfonamide-derived drugs is a contraindication. (Fachinformation zu Triamteren und Hydrochlorothiazid, Gegenanzeigen)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (Fachinformation zu Valsartan und Hydrochlorothiazid, Gegenanzeigen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable. (Fachinformation zu Acetazolamid, Arzneimittelwechselwirkungen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Use with caution in patients with a known hypersensitivity to sulfonamides ( 5.8 ) (Fachinformation zu Almotriptan, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Beta-blockers may decrease effectiveness. (Fachinformation zu Arformoterol, Arzneimittelwechselwirkungen)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (Fachinformation zu Bromocriptin, Arzneimittelwechselwirkungen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Beta-blockers: Use with caution. (Fachinformation zu Budesonid und Formoterol, Arzneimittelwechselwirkungen)

Risk of Hypertension and Bradycardia Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Nonselective Beta-Adrenergic Antagonists Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. (Fachinformation zu Bupivacain, Warnhinweise und Vorsichtsmaßnahmen)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

As with other β-blockers, if COREG is administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored. (Fachinformation zu Carvedilol, Arzneimittelwechselwirkungen)

DRUG INTERACTIONS Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. (Fachinformation zu Cevimelin, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Abrupt discontinuation of QLONILIK can cause rebound hypertension with elevated plasma catecholamines, especially with higher doses or concomitant beta-blocker use. (Fachinformation zu Clonidin, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Intervention: During concomitant use of ZIPSOR and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Diclofenac, Arzneimittelwechselwirkungen)

• During concomitant use of diclofenac sodium/misoprostol and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Diclofenac und Misoprostol, Arzneimittelwechselwirkungen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of Dihydroergotamine Mesylate Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. (Fachinformation zu Dihydroergotamin, Arzneimittelwechselwirkungen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (Fachinformation zu Dofetilid, Arzneimittelwechselwirkungen)

Give a low dose of beta-blockers initially, and increase only after ECG verification of good tolerability [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (Fachinformation zu Dronedaron, Arzneimittelwechselwirkungen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (Fachinformation zu Ergotamin und Koffein, Arzneimittelwechselwirkungen)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Intervention: Patients receiving hydantoins, sulfonamides, or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs. (Fachinformation zu Fenoprofen, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Intervention: During concomitant use of flurbiprofen and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Flurbiprofen, Arzneimittelwechselwirkungen)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

• Beta-blockers may decrease effectiveness. (Fachinformation zu Formoterol, Arzneimittelwechselwirkungen)

Fosamprenavir calcium should be used with caution in patients with a known sulfonamide allergy. (Fachinformation zu Fosamprenavir, Warnhinweise und Vorsichtsmaßnahmen)

…voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen,… (Fachinformation zu Fosphenytoin, Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

Antihypertensives Patients receiving antihypertensive drugs, beta-adrenergic blockers, and nitrates should be observed for possible additive hypotensive effects. (Fachinformation zu Glyceroltrinitrat (Nitroglycerin), Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

During concomitant use of hydrocodone bitartrate and ibuprofen tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Hydrocodon und Ibuprofen, Arzneimittelwechselwirkungen)

Intervention: During concomitant use of CALDOLOR and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Ibuprofen, Arzneimittelwechselwirkungen)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Ibuprofen und Famotidin, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Intervention: During concomitant use of INDOCIN and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Indometacin, Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant Use with Beta Blockers Concomitant use of beta blockers may exaggerate the cardiovascular effects of inhalational anesthetics, including hypotension and negative inotropic effects. (Fachinformation zu Isofluran, Arzneimittelwechselwirkungen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Beta Blockers Nadolol Monitor for adverse reactions. (Fachinformation zu Itraconazol, Arzneimittelwechselwirkungen)

The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (Fachinformation zu Ivabradin, Arzneimittelwechselwirkungen)

Antivirals indinavir, maraviroc, saquinavir Beta Blockers nadolol Calcium Channel Blockers felodipine, nisoldipine other dihydropyridines, verapamil Calcium channel blockers can have a negative inotropic effect which may be additive to those of ketoconazole. (Fachinformation zu Ketoconazol, Arzneimittelwechselwirkungen)

VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (Fachinformation zu Lacosamid, Warnhinweise und Vorsichtsmaßnahmen)

Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Fachinformation zu Lanreotid, Arzneimittelwechselwirkungen)

Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease, may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (Fachinformation zu Ledipasvir und Sofosbuvir, Warnhinweise und Vorsichtsmaßnahmen)

In this setting, cardioselective beta-blockers should be considered, although they should be administered with caution. (Fachinformation zu Levosalbutamol, Arzneimittelwechselwirkungen)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Fachinformation zu Losartan und Hydrochlorothiazid, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: During concomitant use of mefenamic acid and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Mefenaminsäure, Arzneimittelwechselwirkungen)

There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol) (see PRECAUTIONS, Cardiac Effects ). (Fachinformation zu Mefloquin, Arzneimittelwechselwirkungen)

Intervention: During concomitant use of QAMZOVA and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Meloxicam, Arzneimittelwechselwirkungen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (Fachinformation zu Mepivacain, Arzneimittelwechselwirkungen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (Fachinformation zu Methylergometrin, Arzneimittelwechselwirkungen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Patients receiving concomitant negative chronotropic drugs (e.g., beta blockers) may be more at risk for hypotension in case of hypersensitivity reaction. (Fachinformation zu Motixafortid, Warnhinweise und Vorsichtsmaßnahmen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Intervention: During concomitant use of Naproxen Suspension and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Naproxen, Arzneimittelwechselwirkungen)

Intervention : • During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Naproxen und Esomeprazol, Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Fachinformation zu Olmesartan und Hydrochlorothiazid, Warnhinweise und Vorsichtsmaßnahmen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Intervention: During concomitant use of OXAPROZIN CAPSULES and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Oxaprozin, Arzneimittelwechselwirkungen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: • During concomitant use of COMBOGESIC and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (Fachinformation zu Pasireotid, Warnhinweise und Vorsichtsmaßnahmen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (Fachinformation zu Phenelzin, Warnhinweise)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

…voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen,… (Fachinformation zu Phenytoin, Arzneimittelwechselwirkungen)

Drug Interactions Pilocarpine should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances. (Fachinformation zu Pilocarpin, Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

Experience with PONVORY is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate such as digoxin). (Fachinformation zu Ponesimod, Warnhinweise und Vorsichtsmaßnahmen)

Hypotension may develop in patients given prazosin hydrochloride capsules who are also receiving a beta-blocker such as propranolol. (Fachinformation zu Prazosin, Warnhinweise)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Fachinformation zu Probenecid, Arzneimittelwechselwirkungen)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Fachinformation zu Probenecid und Colchicin, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (Fachinformation zu Pyridostigmin, Warnhinweise und Vorsichtsmaßnahmen)

However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim- sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. (Fachinformation zu Pyrimethamin, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Decrease exposure Beta-blockers Metoprolol Decrease exposure Propranolol Decrease exposure Benzodiazepines Diazepam , Administered with rifampin 1200 mg daily Decrease exposure Benzodiazepine-related drugs Zopiclone Decrease AUC by 82% Zolpidem Decrease AUC by 73% Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as… (Fachinformation zu Rifampicin, Arzneimittelwechselwirkungen)

…Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics… (Fachinformation zu Rifapentin, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a rise in systolic blood pressure. (Fachinformation zu Ropivacain, Warnhinweise und Vorsichtsmaßnahmen)

Beta-blockers: Use with caution. (Fachinformation zu Salbutamol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (Fachinformation zu Sofosbuvir und Velpatasvir, Warnhinweise und Vorsichtsmaßnahmen)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (Fachinformation zu Sulfamethoxazol und Trimethoprim (Cotrimoxazol), Arzneimittelwechselwirkungen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Fachinformation zu Telmisartan und Hydrochlorothiazid, Warnhinweise und Vorsichtsmaßnahmen)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Fachinformation zu Terbutalin, Vorsichtsmaßnahmen)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

• Beta-blockers: Use with caution. (Fachinformation zu Umeclidiniumbromid und Vilanterol, Arzneimittelwechselwirkungen)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Zileuton increases propranolol levels and beta-blocker activity. (Fachinformation zu Zileuton, Arzneimittelwechselwirkungen)

• Concomitant use of ZONISADE with any other carbonic anhydrase inhibitor may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation ( 7.2 ). (Fachinformation zu Zonisamid, Arzneimittelwechselwirkungen)

Effects of Adenosine on Other Drugs Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. (Fachinformation zu Adenosin, Arzneimittelwechselwirkungen)

Other Antibacterials Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. (Fachinformation zu Amoxicillin, Arzneimittelwechselwirkungen)

Bacteriostatic Antibiotics : Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins. (Fachinformation zu Ampicillin, Arzneimittelwechselwirkungen)

As with other beta-blockers, when discontinuation of TENORMIN is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. (Fachinformation zu Atenolol, Warnhinweise)

Drug Interactions Bacteriostatic antibacterials ( i.e. , chloramphenicol, erythromycins, sulfonamides or tetracyclines) may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided. (Fachinformation zu Benzylpenicillin (Penicillin G), Arzneimittelwechselwirkungen)

Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. (Fachinformation zu Bisoprolol, Arzneimittelwechselwirkungen)

Allergy to Sulfonamides Patients allergic to sulfonamides may show hypersensitivity to bumetanide. (Fachinformation zu Bumetanid, Warnhinweise)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (Fachinformation zu Carbamazepin, Arzneimittelwechselwirkungen)

Effects on the absorption of other beta-blockers have not been determined. (Fachinformation zu Colestipol, Arzneimittelwechselwirkungen)

Other Cardiovascular Agents Enalaprilat injection, USP has been used concomitantly with digitalis, beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions. (Fachinformation zu Enalaprilat, Arzneimittelwechselwirkungen)

…PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines,… (Fachinformation zu Finasterid, Arzneimittelwechselwirkungen)

Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. (Fachinformation zu Fingolimod, Arzneimittelwechselwirkungen)

Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). (Fachinformation zu Memantin, Arzneimittelwechselwirkungen)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (Fachinformation zu Memantin und Donepezil, Arzneimittelwechselwirkungen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Cross-Allergy Cross-allergy may occur when metolazone tablets, USP, are given to patients known to be allergic to sulfonamide-derived drugs, thiazides, or quinethazone. (Fachinformation zu Metolazon, Warnhinweise)

Pentoxifylline extended-release tablets have been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics, without observed problems. (Fachinformation zu Pentoxifyllin, Arzneimittelwechselwirkungen)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (Fachinformation zu Perphenazin, Arzneimittelwechselwirkungen)

There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. (Fachinformation zu Sulfadiazin-Silber, Warnhinweise und Vorsichtsmaßnahmen)

Angiotensin Receptor Blockers, Angiotensin Converting Enzyme Inhibitors and Potassium Sparing Diuretics Although specific interaction studies were not performed, in clinical studies, tolvaptan was used concomitantly with beta-blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics. (Fachinformation zu Tolvaptan, Arzneimittelwechselwirkungen)

Beta-adrenergic blocking agents: Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials. (Fachinformation zu Ibutilid, Arzneimittelwechselwirkungen)